DGS Capital Management LLC Purchases 1,021 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

DGS Capital Management LLC boosted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 13.1% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 8,809 shares of the biopharmaceutical company’s stock after purchasing an additional 1,021 shares during the period. DGS Capital Management LLC’s holdings in Gilead Sciences were worth $645,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in GILD. Tompkins Financial Corp boosted its position in Gilead Sciences by 223.1% during the 3rd quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 241 shares in the last quarter. Private Wealth Management Group LLC bought a new position in Gilead Sciences during the 4th quarter valued at approximately $29,000. Fortitude Family Office LLC bought a new stake in Gilead Sciences in the fourth quarter worth $29,000. Sachetta LLC purchased a new stake in shares of Gilead Sciences in the fourth quarter worth $30,000. Finally, Rakuten Securities Inc. bought a new position in shares of Gilead Sciences during the fourth quarter valued at $33,000. Institutional investors own 83.67% of the company’s stock.

Insider Activity

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction on Monday, April 1st. The stock was sold at an average price of $72.96, for a total transaction of $145,920.00. Following the completion of the sale, the insider now owns 96,304 shares in the company, valued at $7,026,339.84. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders own 0.16% of the company’s stock.

Gilead Sciences Trading Down 0.7 %

GILD opened at $68.83 on Friday. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $87.86. The company has a debt-to-equity ratio of 1.31, a quick ratio of 0.94 and a current ratio of 1.08. The stock has a market cap of $85.75 billion, a price-to-earnings ratio of 191.19, a P/E/G ratio of 2.95 and a beta of 0.20. The stock’s 50 day moving average price is $65.89 and its 200-day moving average price is $72.75.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) EPS for the quarter, topping analysts’ consensus estimates of ($1.49) by $0.17. The firm had revenue of $6.69 billion for the quarter, compared to analysts’ expectations of $6.36 billion. Gilead Sciences had a net margin of 1.76% and a return on equity of 24.34%. The business’s revenue for the quarter was up 5.3% on a year-over-year basis. During the same period in the prior year, the business posted $1.37 earnings per share. On average, equities analysts forecast that Gilead Sciences, Inc. will post 3.75 EPS for the current year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, June 27th. Stockholders of record on Friday, June 14th were issued a $0.77 dividend. The ex-dividend date was Friday, June 14th. This represents a $3.08 annualized dividend and a dividend yield of 4.47%. Gilead Sciences’s dividend payout ratio is currently 855.56%.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on GILD shares. Robert W. Baird restated a “neutral” rating and issued a $80.00 price objective on shares of Gilead Sciences in a report on Thursday, June 20th. Wells Fargo & Company cut their price objective on Gilead Sciences from $84.00 to $77.00 and set an “equal weight” rating for the company in a report on Monday, March 4th. StockNews.com raised shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research report on Saturday, April 27th. Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a research note on Friday, April 26th. Finally, HSBC raised Gilead Sciences from a “reduce” rating to a “hold” rating and set a $69.00 price objective on the stock in a research note on Wednesday, April 24th. Twelve equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Gilead Sciences has an average rating of “Hold” and an average price target of $83.47.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.